Baseline | 4.3 (3.5–5.3) | 8.7 (7.6–9.7) | 9.3 (8.2–10.3) |
Uncertainty analyses |
Infection parameters |
Anal infection duration doubled (2 years) | 4.3 (3.4–4.8) | 12.5 (11.9– 13.3) | 13.0 (11.9–13.8) |
Anal infection duration halved (0.5 year) | 4.7 (3.8–5.3) | 6.7 (5.6–7.4) | 7.3 (6.3–8.0) |
Behavioural parameters |
Higher frequency of anal sex acts (once per week) | 4.3 (3.4–4.9) | 8.3 (7.6–9.1) | 8.8 (8.2–9.7) |
Lower vaginal sex acts in pairs that also engage in anal sex (same amount of sex acts in both partnerships) | 4.5 (3.9–5.3) | 9.0 (8.1–10.0) | 9.6 (8.8–10.5) |
Higher fraction of people with recent anal sex (30%) | 2.8 (2.3–3.1) | 5.2 (4.6–5.6) | 5.8 (5.3–6.1) |
Treatment parameters |
Lower azithromycin effectiveness for anorectal infection (56%) | 9.0 (7.2–11.6) | 13.4 (11.2–16.0) | 14.0 (11.8–16.5) |
Lower doxycycline effectiveness for anorectal infection (90%) | 2.5 (2.1–2.5) | 6.7 (5.9–7.1) | 7.2 (6.5–7.7) |
Higher azithromycin and doxycycline efficacy for urogenital infection (96.8% and 100%)10 | 4.6 (3.8–5.5) | 8.9 (7.8–9.7) | 9.5 (8.6–10.4) |
Other scenarios |
Azithromycin as the standard of care for anorectal infections4 | 7.0 (6.0–8.5) | 11.4 (10.1–12.9) | 12.1 (10.7–13.4) |
Higher female testing uptake (from 14% to 40% per year) | 4.8 (4.1–5.7) | 9.4 (8.6–10.0) | 10.0 (9.3–10.5) |
Other data source |
Peters et al (South-African primary care facility data)8 | 3.2 (2.7–3.7) | 5.9 (4.4–7.3) | 7.3 (5.9–8.6) |
Østergaard et al (Danish STI clinic data)7 | 4.4 (3.6–5.0) | 9.1 (7.6–9.9) | 9.8 (8.5–10.5) |